The current financial score of PDS Biotechnology Corp is 7.09. Its financial status is robust, and its operating efficiency is low.
The current valuation score of PDS Biotechnology Corp is 6.01. Its current P/E ratio is -1.53, which is -80.32% below the recent high of -0.30 and -448.54% above the recent low of -8.39.
The current earnings forecast score of PDS Biotechnology Corp is 8.00. The average price target is 4.17, with a high of 5.00 and a low of 3.00.
The current price momentum score of PDS Biotechnology Corp is 9.50. Currently, the stock price is trading between the resistance level at 1.49 and the support level at 0.40, making it suitable for range-bound swing trading.
The current institutional shareholding score of PDS Biotechnology Corp is 3.00. The latest institutional shareholding proportion is 17.24%, representing a quarter-over-quarter increase of 61.48%.
No risk assessment score is currently available for PDS Biotechnology Corp. The Biotechnology & Medical Research industry's average is 3.93. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.